spec sheet9 rows
alpha-dihydroergocryptine (almirid/cripar) is a hydrogenated ergot-alkaloid dopamine agonist used for parkinson's disease; a milder, second-tier ergoline agonist with real randomized-trial support for motor symptoms, and the same ergot-class fibrosis caveat as its cousins; it is not a nootropic despite sitting in the ergoline family.
- randomized-trial efficacy as add-on for parkinson's motor complications, better tolerated than lisuride
- possible modestly slower dopamine-transporter decline vs levodopa monotherapy (underpowered pilot)
- milder side-effect profile than some older ergot agonists at comparable use
- long clinical history as a regional antiparkinsonian agent
Mechanism
dihydroergocryptine, used mainly as the alpha isomer, is a hydrogenated ergot alkaloid that works as a -receptor , principally at (and D3), directly stimulating the striatal dopamine receptors that lose their natural input as parkinson's disease kills dopaminergic neurons. like all ergoline agonists it is pharmacologically promiscuous: alongside its dopaminergic action it hits (/2) receptors as a partial agonist and blocks alpha-adrenoceptors, which explains both its mild vasoactive character and its orthostatic-hypotension side effect. clinically the payoff is antiparkinsonian; in a controlled trial it cut l-dopa-associated motor complications more than lisuride and was far better tolerated (battistin et al 1999, doi 10.1111/j.1600-0404.1999.tb00655.x), and a small -spect pilot raised the possibility of a slower nigrostriatal decline than levodopa monotherapy, though it was too small to prove it (poepperl et al 2004, doi 10.1007/s00702-004-0147-6). the molecule also happens to be one of the components of the co-dergocrine (hydergine) mixture, but the standalone drug is used at far higher doses (up to ~60-100 mg/day) for movement rather than the low-dose 'ageing brain' indication. the honest positioning is that this is a legitimate but second-tier, largely regional ergot dopamine agonist that the field mostly moved past once non-ergot agonists (pramipexole, ropinirole) removed the fibrosis liability inherent to the ergot scaffold.
receptor fingerprint
receptoragonist
D3 receptoragonist
/ 5-HT2 receptorspartial agonist (ergoline)
Alpha-adrenoceptorsantagonist
receptorpartial agonist / weak
binding (nigrostriatal)preserves over time vs levodopa (pilot)
Safetyrisks and cautions, not medical advice
Dihydroergocryptine is an ergot-derived dopamine agonist used mainly in Parkinson's disease, and it carries the full ergot-agonist risk set. Common effects include nausea, orthostatic hypotension and somnolence, along with the dopaminergic-class liability for impulse-control disorders (compulsive gambling, shopping, hypersexuality).
The signature serious concern is fibrosis: chronic and high-dose use is linked to valvular heart disease and pleuropulmonary or retroperitoneal fibrosis, plausibly via 5-HT2B receptor activation, with documented pleural fibrosis specifically reported for this drug; fibrosis can progress before symptoms appear. Rarer ergot-structure effects include vasospasm and erythromelalgia. Regulators contraindicate it in patients with pre-existing cardiac valve abnormalities and warn on fibrosis risk with prolonged high-dose therapy, so echocardiographic and imaging surveillance is advised. Sudden-onset sleep also makes driving a documented hazard.
Subjective profileweighing the evidence above
A legitimate second-tier Parkinson's drug with randomized-trial support for motor symptoms, and not a nootropic despite the ergoline family it sits in. The ergot fibrosis risk, including pleural fibrosis documented for this drug specifically, is why it belongs under specialist care.
Resources
This entry is here for reference.
Research
- 1999first citedAlpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind paralle…
- 2006most recentBioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine
- 1.Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study.
- 2.Comparison of alpha-dihydroergocryptine and levodopa monotherapy in Parkinson's disease: assessment of changes in DAT binding with [123I]IPT SPECT.
- 3.Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine
3 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
what is dihydroergocryptine?
it's a hydrogenated ergot alkaloid used as a dopamine-agonist medicine for parkinson's disease, mostly the alpha isomer (alpha-dihydroergocryptine, sold as almirid or cripar in parts of europe). it belongs to the same 'ergoline dopamine agonist' shelf as bromocriptine, cabergoline, pergolide and lisuride, and like them it stimulates dopamine receptors to make up for the dying dopamine neurons in parkinson's.
does it actually work for parkinson's?
yes, in real randomized trials, though it's a second-tier agent. battistin et al randomized l-dopa-treated pd patients to add-on dihydroergocryptine or lisuride and found dihydroergocryptine reduced long-term motor complications better and with far fewer adverse events (25% vs 67%) (doi 10.1111/j.1600-0404.1999.tb00655.x). a small spect pilot even hinted at slower dopamine-transporter decline versus levodopa monotherapy, though it didn't reach significance (doi 10.1007/s00702-004-0147-6).
is it a nootropic?
not really, and that's the honest answer. it lives on this list because it's an ergoline cousin of the vasoactive/nootropic ergots, and older vascular-cognitive literature dabbled with ergot dopamine agonists. but its actual, evidence-backed use is parkinson's motor symptoms, not healthy-brain enhancement. if you came here for cognition, this isn't your compound.
how is it different from bromocriptine or cabergoline?
same class (ergoline dopamine agonists), different potency and tolerability. dihydroergocryptine is generally milder and, in the parkinson's trials, was better tolerated than lisuride. cabergoline is far longer-acting. the big shared caveat is the ergot-class one: all of these carry a risk of fibrosis (heart valves, lung, retroperitoneum) with long-term use, which is exactly why non-ergot agonists (pramipexole, ropinirole) displaced them as first choice.
what dose is used?
in the parkinson's trials it was titrated up to roughly 60 mg/day (and up to ~100 mg/day in some monotherapy work), starting low (5 mg) and stepping up over weeks to limit nausea and low blood pressure. tablets came in 20 mg and 40 mg strengths (de mey et al 2006, doi 10.1055/s-0031-1296712). this is a prescription parkinson's medicine, dosed and monitored by a neurologist.
is it also in hydergine?
sort of; hydergine (co-dergocrine) is a mixture that includes dihydroergocryptine (both alpha and beta isomers) alongside dihydroergocornine and dihydroergocristine. so the molecule overlaps with hydergine's makeup, but as a standalone parkinson's drug it's used at much higher doses and for a completely different purpose than the low-dose 'ageing brain' hydergine tablets.
what are the main side effects?
the dopamine-agonist and ergot ones: nausea, dizziness, orthostatic hypotension (from alpha blockade), sleepiness, and with long-term use the class risk of fibrotic reactions. dopamine agonists as a group can also trigger impulse-control problems (compulsive gambling, shopping, hypersexuality), so that's on the watch list too.
why isn't it more common?
because the field moved on. ergot dopamine agonists were largely replaced by non-ergot agonists once the fibrosis risk became clear, and dihydroergocryptine was never a top-tier agent to begin with; it's mostly a european/regional product. it's a legitimate, studied drug, just not a modern first-line one.